Latest Conference Articles

Explore groundbreaking findings from the REDEFINE trials on CagriSema's impact on weight loss and diabetes management at ADA 2025.

Philis-Tsimikas shared the latest findings demonstrating inferiority after switching from daily basal insulin to weekly insulin efsitora.

Kevin Sayer joins the program to discuss the latest from Dexcom and preview where the business is headed in an evolving diabetes landscape.

A new study reveals once-weekly efsitora alfa effectively lowers blood glucose in type 2 diabetes.

Steger discussed findings from a 6-month lifestyle investigating TRE+ER and IER.

CagriSema shows weight loss results in recent trials comparable to existing interventions.

Xue discussed her research developing a personalized prediction algorithm for predicting responders to a DPP-style intervention.

A phase 3 trial reveals ecnoglutide significantly reduces body weight in overweight patients, showcasing its potential as a novel obesity treatment.

A new study reveals hybrid closed-loop technology significantly improves glucose control for pregnant women with T1D.

Semaglutide 7.2 mg shows promising results, achieving a mean 21% weight loss in obesity treatment.

The ACHIEVE-1 trial reveals orforglipron's potential as a breakthrough treatment for type 2 diabetes.

New research reveals amycretin's promising potential for weight loss in obesity treatment, advancing to phase 3 trials for effective management options.

Most participants (83%) did not require exogenous insulin 1 year after zimislecel (VX-880) infusion.

New ADA guidelines enhance obesity care, focusing on personalized treatment, bias reduction, and inclusive practices to improve patient outcomes.

These data from RAD 2025 highlight upadacitinib’s efficacy in the phase 3 Measure Up 1 and 2 studies for older adults with atopic dermatitis.

At SLEEP 2025, Malhotra emphasized the need for weight loss to resolve obesity hypoventilation syndrome and highlighted limitations of current therapies.

At SLEEP 2025, Malhotra shared updates on diagnosing and managing OHS, including the role of bicarbonate, PAP use, and weight loss.

From barriers to implementing evidence-based care to innovations in combination therapy, here are 5 key updates from the annual meeting.

A study presented at SLEEP 2025 found longer and more variable napping patterns are associated with increased all-cause mortality in middle-to-older aged adults.

This Q&A interview at RAD 2025 features a discussion about a talk titled ‘Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis.’

At SLEEP 2025, HCPLive spoke to Strollo about the phase 3 SynAIRgy trial which evaluated AD109, a first-in-class, once-daily oral neuromuscular modulator, for OSA.

At SLEEP 2025, Cassiere discussed how pulse oximetry inaccuracies among patients with darker skin tones may lead to underdiagnosis or misclassification of sleep apnea severity.

At SLEEP 2025, Lillis discussed how wearable data revealed disruptions in sleep consolidation up to 13 weeks postpartum despite total sleep duration nearing pre-pregnancy levels.

An overview of 7 presentations included as late-breaking clinical trials at ADA 2025.

By week 2 postpartum, sleep duration rebounds, but fragmented sleep persists through week 13, Teresa Lillis, PhD, presented at SLEEP 2025.

At SLEEP 2025, Walia discussed findings showing Hispanic individuals may experience more severe cases of sleep disordered breathing compared to the non-Hispanic group.

At SLEEP 2025, Bruce Corser, MD, discussed promising open-label data on pitolisant’s impact on idiopathic hypersomnia symptoms with HCPLive.

At SLEEP 2025, Winkelman discussed the AASM’s updated guidelines urging clinicians to transition patients with RLS off dopamine agonists due to augmentation risks.